1. |
[1]Mathieu E,Fain O,Sitbon M,Thomas M.Systemic adverse effect of antithyroid drugs[J].Clin Rheumatol,1999; 18(1):66-68.
|
2. |
[2]Rodrigue S,Laborde H,Catoggio PM.Systemic lupus erythematosus and thyrotoxicosis:a hitherto little recognised association.Ann[J].Rheum Dis,1989; 48(5):424-427.
|
3. |
[3]Xu X,Zhao M,Zhang Y,Guo X,Wang H.Clinicopathological characteristics of propylthiouracil-induced antineutrophil cytoplasmic antibodies-positive vasculitis and their target antigens:a report of 4 cases and literature review[J].Chinese Journal of Internal Medicine,2002; 41(6):404-407.
|
4. |
徐旭東,趙明輝,章友康,郭曉惠,王海燕.丙基硫氧嘧啶導致的抗中性粒細胞胞質抗體陽性小血管炎及其靶抗原研究[J].中華內科學雜志,2002; 41(6):404~407.
|
5. |
[4]Yamada A,Sato K,Hara M,Tochimoto A,Takagi S,Hizuka N,Takano K.Propylthiouracil-induced lupus-like syndrome developing in a Graves’ patient with a sibling with systemic lupus erythematosus[J].Intern Med,2002; 41(12):1 204-1 208.
|
6. |
[5]Kawasaki Y,Suzuki J,Sike T,Isome M,Nozawa R,Suzuki S,Kume K,Suzuki H.A pediatric case of myeloperoxidase-antineutrophil cytoplasmic (ANCA)-related crescentic glomerulonephritis associated with propylthiouracil treatment for Graves’ disease[J].Nippon Jinzo Gakkai Shi,1998; 40(8):612-617.
|